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Introduction
The relative number of cardiac device infections is rising 
together with an increase in device implantations [1–3]. 
Cardiac device infection is associated with substantial mor-
bidity and mortality [1, 2]. Risk factors associated with 
device infections are the number of previous device pro-
cedures, renal insufficiency, post-procedural haematoma, 
fever < 24 h after the procedure, and complexity and dura-
tion of the procedure [1, 4, 5].
The Isala is a large volume tertiary care heart centre, 
with advanced experience in the management of cardiac 
device complications, including infections. We previously 
published on lead dysfunction rates in our hospital [6]. Due 
to the rising number of cardiac device infections, a nation-
wide program was initiated from the National Society of 
Cardiology (NVVC) in the Netherlands in 2008 in order to 
reduce the incidence along with its morbidity and mortality 
rates. Especially for implantable cardioverter defibrillators 
(ICDs), infection and complication rates were registered. 
At present, limited data are available regarding complica-
tions of cardiac device implantations in the Netherlands. 
Our main goal, therefore, was to examine the frequency, 
characteristics and possible risk factors for cardiac device 
infections in our large volume centre.
Methods
Standardly, device procedures were performed in the 
cathlab; however, when submuscular device implantations 
  A. Elvan
v.r.c.derks@isala.nl
1 Department of Cardiology, Isala Hospital, Dr. Van Heesweg 
2, 8025 AB Zwolle, The Netherlands
Abstract
Aims To determine the frequency, characteristics and risk 
factors of cardiac device infections in the Isala Hospital.
Methods We retrospectively studied all patients who un-
derwent cardiac device procedures performed in the cardiac 
catheterisation lab and the operating room from 2010 to 
2012. All patients who developed a cardiac device infection 
were reviewed for its characteristics.
Results 31/2026 patients developed a cardiac device in-
fection (1.5 %). One (3.2 %) patient died within 30 days 
of hospitalisation. Device infection rates for procedures 
in the catheterisation lab and operating room were similar 
(p = 0.60). Positive cultures were present in 27/31 (87 %) 
cases. These consisted predominantly of micro-organisms 
that are part of the skin flora (84 %). The mean time between 
device procedure and infection was 14 ± 21 months (range 
0–79). Cardiac device infection was significantly associated 
with device revision, (65 % were revisions in patients with 
device infection vs. 30 % revisions in patients without de-
vice infection, p = 0.011) and placement of a left ventricular 
lead in pacemaker implantations (59 % of patients with vs. 
51 % of patients without device infection, p < 0.001).
Conclusion The frequency of cardiac device infection was 
1.5 % with a mortality of 3.2 % within 30 days, which is 
lower compared with other registries. Cardiac device infec-
tions were associated with device revisions and placement 
of left ventricular leads in pacemaker implantations.
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anaesthesiologist, and with continuous transoesophageal 
echocardiographic monitoring. We did not use Laser when 
requiring a powered extraction tool. When lead vegetations 
with a magnitude of > 3 cm or valvular endocarditis were 
present, the open chest procedure was performed with the 
cardiothoracic surgeon in the operating room. Cultures 
were systematically obtained from the blood and the device 
pocket during extraction. If re-implantation of a new device 
was performed, this took place on the contralateral side 
and at least one week after the last negative blood culture. 
Pacing-dependent patients received a temporary pacemaker 
via the contralateral jugular vein when a percutaneous lead 
extraction was performed, or epicardial leads when surgery 
had to be performed to remove all device-related material.
Statistical analysis
Continuous variables are reported as mean ± standard 
deviation. Categorical variables are reported as number 
and percentage. Normality of distribution was tested by the 
Kolmogorov-Smirnov test or distribution plots. Statistical 
significance between differences was calculated by Chi-
squared test, Fisher’s exact test, Mann-Whitney or student-
T-test where appropriate. P-values (two-sided) ≤ 0.05 were 
considered statistically significant. Statistical analysis was 
performed using SPSS v17.0 (SPSS Inc, Chicago).
Results
During the study period, 2026 device-related procedures 
(excluding device infection-related procedures) were per-
formed in 1867 patients. Of these procedures, 1702 (84 %) 
took place in the cardiac catheterisation lab used specifically 
for cardiac electrophysiological procedures and 324 (16 %) 
in the operating room. There were 1180 primary implan-
tations and 846 revisions (mostly generator replacement). 
Device replacement was performed in 771 procedures and 
there were 75 lead revisions without device replacement. 
The proportion of revisions on the operating room was 30 % 
for pacemakers and 34 % for ICDs, whereas this was 23 % 
for pacemakers and 14 % for ICDs in the catheterisation lab.
In 31 of 2026 procedures (1.5 %), a cardiac device infec-
tion occurred during follow-up. Of these 31 cases, 13 had a 
primary implantation in secondary care centres in the area. 
There were no patients lost to follow-up. The mean time 
between device procedure and device infections was 14 ± 21 
months (0–79 months). Clinical characteristics of patients 
with a device infection are presented in Table 1. In 6 cases 
(19 %) a device infection occurred within one month after 
the primary implantation or revision and in 8 cases (26 %) 
the device infection was more than 1 year after the last 
were planned, or procedures were under general anaes-
thesia, the operating room was used. All patients who 
underwent cardiac device procedures were treated with 
prophylactic antibiotics (cefazolin 1 gram intravenously) 
1 h before and 3 h after the procedure. At the discretion of 
the operator, antibiotic treatment was continued with oral 
clindamycin (mostly in device revisions). We reviewed all 
cases of cardiac device infection between 1 January 2010 
and 31 December 2011. Cases were identified from a retro-
spectively studied prospective registry including all patients 
who underwent a cardiac device procedure in the Isala in 
Zwolle, the Netherlands. There were no exclusion criteria. 
Independent research assistants registered pre-defined data 
in an electronic research form. These data included age, 
sex, known risk factors for cardiac device infections such 
renal insufficiency, number of leads, type of device, time 
after device procedure and number of device procedures. 
Patients were followed according to the standard routine at 
the outpatient clinic, 6–8 weeks after device procedure, and 
at 6-month intervals thereafter, or more frequently when 
deemed necessary. Generally, cardiac resynchronisation 
therapy and ICDs were monitored in the Isala, and not in 
the referring centre. If controls were performed in a referral 
centre, we obtained information regarding the patient from 
that referring centre. A thorough screening of the medical 
files was performed in all cases. The diagnosis of cardiac 
device infection was based on the combination of suspected 
clinical history, signs of pocket infection on physical exam-
ination, and with transthoracic and/or transoesophageal 
echocardiography where appropriate. A second physician 
specialised in cardiac device implantations (e.g. a cardiac 
electrophysiologist) validated the diagnosis. In all cases 
blood cultures were taken. When a device infection was 
present, e.g. a pocket infection or device-related endocardi-
tis, the standard treatment was to remove all device material 
and aggressively treat the patient with culture-guided intra-
venous antibiotics for a period of 2–6 weeks (depending on 
the type of infection). Lead extraction was performed using 
a standard stepwise approach in all patients. After leads 
were dissected free from the scar tissue in the pocket, the 
anchor sleeves were removed and the active fixation mecha-
nism was retracted. After that, controlled manual traction 
was attempted. If the lead could not be easily removed, then 
an appropriately sized locking stylet (Liberator Universal 
locking stylet, Cook Vascular, USA) was placed, and a silk 
suture was tied around the lead to bind the insulation to the 
conductors and to keep the insulation from bunching in 
front of the sheath. Controlled manual traction was again 
attempted with the locking stylet in place, making sure not 
to disrupt the lead integrity. If still unsuccessful a hand-
powered mechanical rotational dilator Evolution sheath was 
used. All patients requiring this sheath underwent the pro-
cedure under general anaesthesia supervised by a cardiac 
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performed in the cardiac catheterisation lab or the operating 
room (p = 0.60).
Aetiology of cardiac device infection
In all 31 cases multiple blood, device and lead cultures were 
taken. In 87 % of the cases (27/31) cultures were positive. 
In 12/27 cases (44 %) blood cultures were positive, in 67 % 
(18/27) a micro-organism was isolated from the pocket/
wound and in 48 % micro-organisms were found at the 
extracted leads. These consisted predominantly of micro-
organisms that are part of the skin flora (84 %). Staphylo-
coccus aureus and Staphylococcus epidermidis were the 
most frequently found pathogens of device infection in this 
study. An overview of rates of device infection pathogens is 
presented in Fig. 2.
When we compare the characteristics of cases of cardiac 
device infections with all cardiac device procedures, device 
revision was significantly associated with device infection 
(65 % of patients with a device infection had a revision 
vs. 30 % of patients without infection, p = 0.01). No differ-
ence was observed, however, for time to device infection 
between device revisions and primary implantations (323 
days for revision vs. 655 days for primary implantation, 
p = 0.15). Further, placement of a left ventricular lead in 
pacemaker implantations was associated with device infec-
tion (59 % of patients with vs. 51 % of patients without 
infection, p < 0.001). All other characteristics described in 
Table 2 were not significantly different.
device procedure. Thus, about 60 % of the device infections 
occurred in the first year (Fig. 1).
All patients with cardiac device infections underwent 
extraction of all device-related material. Only a pocket 
infection was present in 24 of 31 these patients. In 7 of the 
31 cases (23 %), besides a pocket infection, lead endocar-
ditis with vegetations was present. In one case there was 
involvement of the tricuspid valve, which was successfully 
treated conservatively with antibiotics. All cases of car-
diac device infections were treated percutaneously in the 
operating room. In 8 cases a temporary lead was needed. 
One patient developed vegetations in the right atrium, after 
a percutaneous extraction of the whole system, and these 
vegetations had to be removed surgically. One patient 
died within 30 days (3.2 % mortality in patients with car-
diac device infections and 0.05 % mortality compared with 
the whole study cohort); unfortunately the cause of death 
could not be identified. When follow-up was extended to 1 
year, 1 additional patient died, however not due to a device 
infection or its consequences. The 1-year mortality was not 
significantly different (p = 0.92) compared with the control 
group (112/1867, 6.0 %). No difference was present in the 
frequency of cardiac device infections between procedures 
Table 1 Characteristics of patients with a cardiac device infection
Age 69 ± 18 (years)
% Male 61 % (19)
BMI 26 ± 4 (kg/m2)
Diabetes mellitus 5 (16 %)
Renal failurea 1 (3,2 %)
Mean creatinine 121 ± 19 (μmol/L)
Malignancy 3 (10 %)
Primary implantation 11 (35 %)
Revision 20 (65 %)
Device revision 14 (70 %)
Lead revision 4 (20 %)
Upgrade 2 (10 %)
Pacemaker 17 (55 %)
1–2 leads 13 (76 %)
2 + leads 4 (24 %)
ICD 14 (45 %)
1–2 leads 11 (79 %)
2 +  leads 3 (21 %)
Last procedure in OR 3 (10 %)
Last procedure in CCL 28 (90 %)
Time after revision 323 days (13-1677)
Time after implantation 655 days (14-2472)
Vitamin K antagonist 15 (48 %)
Corticosteroid use 0 (0 %)
BMI body mass index, ICD implantable cardioverter defibrillator, OR 
operating room, CCL cardiac catheterisation lab.
aThe eGFR was calculated by the MDRD formula. Renal failure was 
defined as an eGFR < 30.
Fig. 1 Overview of cumulative cardiac device infections with time 
after procedure (months) on the X-axis and number of infections (in 
percentage of total) on the Y-axis
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The reported 30-day mortality rate in our study was 
as low as 3.2 % and 1 year all-cause mortality rates were 
similar to patients without device infection. Again, mortal-
ity rates were lower in our present report, in comparison 
with other reports, which had mortality rates of 7.4–23 % [3, 
10–12]. In these reports, however, only 8–41 % of patients 
underwent complete removal of the device and leads [11, 
12]. Thus, our lower mortality rate could be caused by our 
aggressive approach of fast and complete system removal, 
preferably percutaneously, with aggressive and prolonged 
antibiotic treatment. The current European Society of Car-
diology guidelines support this practice [13].
Risk factors for device infection were device revision and 
left ventricular lead placement. In our present report, this was 
the case in pacemakers but not in ICDs. We had expected 
that in both groups, a higher number of leads would be 
related to device infection, mainly because of the procedure 
duration. Differences in clinical characteristics of pacemaker 
versus ICD patients could be of influence in explaining this 
unexpected finding in our present report. Unfortunately, we 
could not perform multivariate analysis correcting for con-
founders, due to the low number of endpoints. The exact 
relation can therefore not be extracted from our database, 
and to refrain from hypothetical discussion, we decided not 
to speculate on this. Most previous reports indicate that a 
higher number of previous device procedures is one of the 
most important risk factors for device infection. Addition-
ally, procedure time, pocket haematoma, procedure duration, 
renal dysfunction, low body mass index, diabetes and steroid 
use have been reported as risk factors [5, 14, 15]. It is at pres-
ent unknown if prolonged use of prophylactic antibiotics in 
patients at high risk for device infection reduces the rate of 
device infection. Recently, an antibacterial envelope placed 
around the device generator in the pocket was developed, 
possibly further reducing infection rates [16].
Discussion
Our present study shows that the incidence of cardiac device 
infection in our hospital is 1.5 %, and is mainly caused by 
skin-related bacteria. Risk factors associated with device 
infection are device revision (e.g. generator change) and 
number of pacemaker leads.
The reported rate of cardiac device infection throughout 
the world ranges between 0.8–5.8 % [7–9]. At 1.5 %, the 
reported frequency in our hospital is relatively low. Possi-
bly, the aggressive protocol for periprocedural prophylac-
tic antibiotics in patients at high risk for device infection 
(mainly in patients with device revisions with additional 
lead placement, or when procedure durations were longer 
than 3 h) could have contributed to this. In general, the 
high level of experience of operating physicians is associ-
ated with lower rates of infection. The true infection rate 
might be even lower, because 13/31 patients had a primary 
implantation in the referring hospital.
Table 2 Comparison between case of cardiac device infection (CDI) 
and all cases
CDI All cases 
(minus CDI)
p-value
Age 69 ± 19 67 ± 13 p = 0.667
% Male 19/31 1259/1867 p = 0.469
Diabetes mellitus 5/31 313/1867 p = 0.925
Renal failure 1/31 42/1744 p = 0.769
Device revision 20/31 846/2026 p = 0.011
Pacemaker 17/31 468/1180 p = 0.089
3 leads 6/17 24/468 p < 0.0001
ICD 14/31 692/1180 p = 0.089
3 leads 3/14 233/692 p = 0.336
Vitamin K antagonist 15/31 689/1867 p = 0.189
All-cause mortality 2/31 112/1867 p = 0.916
Fig. 2 Micro-organisms found 
responsible for cardiac device 
infections
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In our present study, no significant difference was seen in 
cardiac device infection rate between device procedures that 
were performed in the catheterisation lab and the operating 
room. This is supported by the observations by Sohail et al. 
[15]. Possibly, this can be explained by the fact that most 
device infections are caused by skin-related micro-organ-
isms, and could be introduced during the postoperative 
period, or thereafter. Most device infections were caused 
by Staphylococcus species commonly found on the human 
skin. Caution is needed with interpretation of the device 
and lead cultures, since there is a chance of contamination 
which might have led to false-positive cultures. There was 
an early infection rate (e.g. <1 month) of 23 %. It is likely 
that early infection is caused by primary contamination dur-
ing the device procedure or in the directly following period. 
For the device infections that occur in a later time frame, 
it is not always easy to determine the cause of the infec-
tion. In one patient, in this study, device infection occurred 
after elective surgery for varicose veins. Iatrogenic causes 
of infection play a role in device infection, but it would be 
hard to lower the rate of this since it is common practice 
to give patients prophylactic antibiotics for most surgical 
procedures.
Limitations
A major limitation is that we retrospectively analysed our 
database from a single centre. Since patients were followed 
once per 6 months, and we did not actively search for pos-
sible device infections between the regular follow-up visits, 
we could have missed possible patients with a device infec-
tion with symptoms not severe enough for the patient to 
attend to the hospital. Not all clinical variables were avail-
able for analysis (e.g. duration of the procedure and inci-
dence of pocket haematoma), precluding the possibility to 
find associations of these variables with device infection. 
Another limitation is the fact that we compared two groups 
that were possibly not comparable at baseline due to the ret-
rospective design of the study.
Conclusion
We report relatively low numbers of device infection inci-
dence, and low mortality rates when patients are prophylac-
tically treated with antibiotics and, in case of an infection, 
treated aggressively. Risk factors for device infection were 
device revision and placement of left ventricular leads, and 
were mainly caused by skin-related bacteria.
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